RxDoctor Payments DataLook up a doctor →

David Sackel, MD

Ophthalmology · Atlanta, GANPI 1235459512

Payments from drug & device makers

$81,766in general payments, 2019–2025

Across 623 payments — averaging $131.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$53K
  • Alcon$9K
  • Glaukos Corporation$4K
  • Harrow Eye, LLC$2K
  • Sight Sciences, Inc.$2K
  • Biotissue Holdings Inc.$2K
  • plus $9K from 25 others

What the payments were for

  • Consulting fees$50,24961%
  • Speaking & faculty fees$3,3394%
  • Travel & lodging$2,3293%
  • Food & beverage$24,40030%
  • Education$5001%
  • Gifts$190%
  • Other$9301%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,766 in reported general payments places this provider in the 90th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$352,338
Medicare patients
836
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast57$71,221
RestasisCyclosporine54$60,226
CequaCyclosporine27$31,789
MieboPerfluorohexyloctane/Pf20$20,320
VevyeCyclosporine18$19,219
Prednisolone Acetate360$15,316
LumiganBimatoprost21$12,451
CombiganBrimonidine Tartrate/Timolol29$9,152
Cyclosporine17$8,232
Loteprednol Etabonate37$6,417
MoxifloxacinMoxifloxacin Hcl239$4,858
ValacyclovirValacyclovir Hcl79$2,549
Latanoprost157$2,474
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$1,873
Tobramycin-DexamethasoneTobramycin/Dexamethasone38$1,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$428$91,54177 claims
AbbVieRestasis, Lumigan, Combigan$725$81,829104 claims
Sun Pharmaceutical Industries Inc.Cequa$1,261$31,78927 claims
Harrow Eye, LLCVevye$2,273$19,21918 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$158$6,41737 claims
Eyevance Pharmaceuticals LLCFlarex$351$1,36911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →